These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36333064)

  • 1. Contemporary and future strategies in polycythemia vera.
    Waksal JA; Tremblay DA
    Best Pract Res Clin Haematol; 2022 Jun; 35(2):101370. PubMed ID: 36333064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Austrian recommendations for the management of polycythemia vera.
    Burgstaller S; Buxhofer-Ausch V; Sliwa T; Beham-Schmid C; Gastl G; Geissler K; Melchardt T; Krauth M; Krippl P; Petzer A; Rumpold H; Wölfler A; Gisslinger H
    Wien Klin Wochenschr; 2018 Sep; 130(17-18):535-542. PubMed ID: 30027395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
    Stein BL; Moliterno AR; Tiu RV
    Ann Hematol; 2014 Dec; 93(12):1965-76. PubMed ID: 25270596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera: the current status of preclinical models and therapeutic targets.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.
    Benevolo G; Marchetti M; Melchio R; Beggiato E; Sartori C; Biolé CA; Rapezzi D; Bruno B; Milan A
    Vasc Health Risk Manag; 2023; 19():765-778. PubMed ID: 38025519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future treatment options for polycythemia vera.
    Griesshammer M; Gisslinger H; Mesa R
    Ann Hematol; 2015 Jun; 94(6):901-10. PubMed ID: 25832853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of symptoms in polycythemia vera and essential thrombocythemia patients.
    Radia D; Geyer HL
    Hematology Am Soc Hematol Educ Program; 2015; 2015():340-8. PubMed ID: 26637741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.
    Goulart H; Mascarenhas J; Tremblay D
    Ann Hematol; 2022 May; 101(5):935-951. PubMed ID: 35344066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat polycythemia vera.
    Passamonti F
    Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive Hepatic Infarction due to Polycythemia Vera.
    Furukawa K; Urano F; Okamura S; Kawashima H
    J Gastrointestin Liver Dis; 2024 Mar; 33(1):18. PubMed ID: 38554424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
    Maffioli M; Mora B; Passamonti F
    Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.